Alpha Teknova, Inc. reported a revenue of $10.5 million for the third quarter of 2025, marking a 9.2% increase from $9.6 million in the same period last year. For the nine months ending September 30, 2025, the company generated $30.5 million in revenue, up 7.2% from $28.5 million in the prior year. The growth in revenue was primarily driven by a 16% increase in the Lab Essentials product category, which accounted for $8.3 million in the latest quarter. However, revenue from Clinical Solutions decreased by 13.1% to $1.7 million, attributed to lower average revenue per customer despite an increase in customer count.
The company's cost of sales decreased significantly by 23.6% to $7.2 million for the third quarter, contributing to a gross profit of $3.2 million, a substantial increase from just $90,000 in the same quarter of 2024. This resulted in a gross profit margin of 30.7%, compared to 0.9% in the previous year. For the nine-month period, gross profit nearly doubled to $10.2 million, reflecting a gross profit margin of 33.4%, up from 17.9% in 2024. The improvement in profitability was largely due to the absence of non-recurring charges related to inventory disposal that impacted the previous year’s results.
Operating expenses for the third quarter decreased by 4% to $7.2 million, with notable reductions in research and development costs, which fell by 13.6% to $542,000. General and administrative expenses also declined by 6.5% to $4.6 million. The company reported a loss from operations of $4.0 million for the quarter, significantly improved from a loss of $7.4 million in the same period last year. For the nine months, the operating loss was $12.4 million, down from $20.5 million in 2024, indicating a 39.7% reduction in losses.
As of September 30, 2025, Alpha Teknova's total assets were valued at $107.6 million, down from $118.8 million at the end of 2024. The company had cash and cash equivalents of $3.2 million, alongside short-term investments of $18.9 million. The total liabilities decreased to $35.0 million, with long-term debt net increasing to $13.1 million from $9.4 million at the end of 2024. The company’s workforce was reduced by approximately 35 positions in early 2024 to streamline operations and reduce costs.
Looking ahead, Alpha Teknova anticipates continued investment in its infrastructure and personnel to enhance operational efficiency and expand capacity. The company is closely monitoring economic conditions, including inflation and interest rates, which could impact customer demand and operational costs. Despite these challenges, Teknova remains focused on its strategic goals, including the ramp-up of new manufacturing facilities and the expansion of its customer base across the life sciences market.
About Alpha Teknova, Inc.
Alpha Teknova, Inc. manufactures custom chemical reagents and media critical for life sciences research, drug development, and molecular diagnostics. Serving pharmaceutical, biotechnology, diagnostics, and academic customers, it offers pre-poured media plates, cell culture media, and molecular biology reagents. Its adaptable manufacturing processes enable rapid, scalable production of research-use and GMP-grade products, supporting customers from discovery through commercialization with high quality, fast turnaround, and regulatory compliance.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.